share_log

Xenetic Biosciences | SC 13D: Statement of acquisition of beneficial ownership by individuals-CLS Therapeutics Ltd.(9.7%),Dmitry Genkin(9.7%), etc.

SEC ·  Jun 16, 2023 05:20
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.